Inclusion Criteria:

1. All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study.

2. Patients must have histologically or cytologically confirmed low or intermediate
grade neuroendocrine tumor, for which standard curative measures do not exist.
Patients with neuroendocrine tumors associated with multiple endocrine neoplasia type
1 (MEN1 syndrome) will be eligible.

3. Patients must have liver-only or liver-dominant disease.

4. Patient deemed suitable for TheraSphere therapy after review of anatomic imaging by
an Interventional Radiologist.

5. No prior biliary enteric anastomosis.

6. Intact portal vein and hepatic artery.

7. Age >/= 18 years of age.

8. World Health Organization (WHO) performance status of 0 or 1.

9. Patients must have normal organ and marrow function as defined below: a) leukocytes
>/= 3,000/mcL; b) absolute neutrophil count >/= 1,500/mcL; c) hemoglobin >/= 9 g/dL*;
d) platelets >/= 100,000/mcL; e) total bilirubin (ULN); f) AST (SGOT) and ALT (SGPT) test [LFT] elevations due to liver metastases); g) creatinine ULN OR creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels
above institutional normal. *Eligibility level for hemoglobin may be reached by
transfusion.

10. The patient must have fasting serum glucose
11. Fasting serum cholesterol patient can only be included after initiation of appropriate lipid lowering
medication.

12. The effects of TheraSphere and everolimus on the developing human fetus are unknown.
For this reason, women of child-bearing potential must agree to use highly effective
contraception from the time of study enrollment continuing for the duration of study
therapy and for 8 weeks after the last dose of TheraSphere and/or everolimus. Women
of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, must use highly effective contraception during the study and for 8 weeks
after stopping treatment. Highly effective contraception is defined as either: 1)
Total abstinence: When this is in line with the preferred and usual lifestyle of the
subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of contraception.];

13. Continuation of # 12: 2) Sterilization: have had surgical bilateral oophorectomy
(with or without hysterectomy) or tubal ligation at least six weeks before taking
study treatment. In case of oophorectomy alone, only when the reproductive status of
the woman has been confirmed by follow up hormone level assessment; 3) Male partner
sterilization (with the appropriate post-vasectomy documentation of the absence of
sperm in the ejaculate). [For female subjects on the study, the vasectomised male
partner should be the sole partner for that subject.]; 4) Use of a combination of any
two of the following (a+b or a+c or b+c): a. Use of oral, injected, implanted or
other hormonal methods of contraception; b. Placement of an intrauterine device (IUD)
or intrauterine system (IUS); c. Barrier methods of contraception: Condom or
Occlusive cap (diaphragm or cervical/vault caps) with spermicidal
foam/gel/film/cream/vaginal suppository.

14. Continuation of # 13: In case of use of oral contraception, women should have been
stable on the oral agent before taking study treatment. Sexually active males must
use a condom during intercourse while taking the drug and for 8 weeks after stopping
treatment and should not father a child in this period. A condom is required to be
used also by vasectomised men in order to prevent delivery of the drug via seminal
fluid. Female partners of male patients must also be advised to use one of the
following contraception methods: Use of (1) oral, injected, implanted or other
hormonal methods of contraception, or (2) intrauterine device (IUD) or intrauterine
system (IUS), or (3) prior male/female sterilization.

15. Women of childbearing potential must have a serum pregnancy test within 7 days prior
starting study treatment.

16. Patients must have at least one measurable site of disease according to RECIST in
liver.

17. Patients may have received prior systemic anti-neoplastic therapy. There are no
limitations on the number of prior regimens. At least 28 days must have elapsed since
last treatment. Prior somatostatin analogs use is allowed. The patients on 3 months
of stable dose of concurrent somatostatin analogs will be allowed to continue while
on study treatment.

18. Patients must have international normalized ratio (INR)
Exclusion Criteria:

1. Patients may not be receiving any other treatment-related investigational agents.

2. Uncontrolled intercurrent illness including but not limited to: a) ongoing or active
infection requiring parenteral therapy at the time of study registration; b) liver
disease such as cirrhosis or severe hepatic impairment (Child-Pugh class B or C)
Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be
done at screening for all patients. Testing required at screening for all patients
with a positive medical history based on risk factors and/or confirmation of prior
HBV/HCV infection; c) symptomatic congestive heart failure resulting in a resting O2
saturation of < 92% on room air; d) unstable angina or pectoris myocardial infarction
within 6 months of start of study drug; e) serious uncontrolled cardiac arrhythmia;
f) known severely impaired lung function as defined as spirometry and DLCO that is
50% of the normal predicted value and/or oxygen saturation that is 88% or less at
rest on room air. Pulmonary function test (PFT) is not required at study entry.

3. Patients currently receiving anticancer therapies or who have received anticancer
therapies within 4 weeks of the start of study drug (including chemotherapy,
radiation therapy, antibody based therapy, etc.).

4. Patients, who have had a major surgery or significant traumatic injury within 4 weeks
of start of study drug, patients who have not recovered from the side effects of any
major surgery (defined as requiring general anesthesia) or patients that may require
major surgery during the course of the study.

5. Patients who previously received liver directed therapy, with either radiofrequency
ablation (RFA), transarterial hepatic embolization (TACE) with or without
chemotherapy must have >/= 60 days elapsed since last treatment.

6. A known history of human immunodeficiency virus (HIV) seropositivity.

7. Chronic treatment with systemic steroids or another immunosuppressive agent.

8. Female patients who are pregnant or breast feeding, or of reproductive potential who
are not using effective birth control methods.

9. Patients with a known history of allergic reactions and/or hypersensitivity
attributed compounds of similar chemical or biologic composition to everolimus or
other rapamycins (sirolimus, temsirolimus).

10. Known history of brain or leptomeningeal metastases.

11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study enrollment or anticipation of need for major surgical procedure during
the course of the study.

12. Patients who have had hormonal therapy (other than replacement) within 4 weeks prior
to entering the study.

13. Not recovered from adverse events related to previous treatment (excluding alopecia)
to active Common Terminology Criteria for Adverse Events (CTCAE) Ver. 4
14. With the exception of tumor common to a single genetic cancer syndrome (ie MEN1,
MEN2, von Hippel-Lindau [vHL], tuberous sclerosis complex [TSC] etc), patients with
evidence of more than one active malignancy are excluded. Active malignancy is
defined as the presence of primary, regional nodal, or distant metastatic neoplasm
that has not undergone definitive therapy.

15. The patient has poorly controlled diabetes mellitus. Patients with a history of
diabetes mellitus are allowed to participate, provided that their blood glucose is
within 1.3 X institutional upper limit of normal and that they are on a stable
dietary or therapeutic regimen for this condition.

16. Patients who have received prior treatment with everolimus or an mTOR inhibitor
(sirolimus, temsirolimus, everolimus).